

**ondine**



**For Immediate Release**

## **Ondine Receives Health Canada License for the Treatment of Outer Ear Infections**

**Vancouver, Canada – May 26, 2008** - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP), a medical technology company developing photodisinfection-based products, today announced it received a Health Canada license for its non-antibiotic Photodisinfection System for the treatment of Otitis Externa, outer ear infections.

“Obtaining this additional Health Canada license for the treatment of chronic and acute Otitis Externa is indicative of the broad applicability and versatility of our Photodisinfection technology,” stated Carolyn Cross, Ondine’s President and CEO. “We believe that photodisinfection technology is an effective, non-antibiotic approach for the destruction of pathogens associated with topical infections. We intend to undertake a search for an appropriate strategic partner for the commercialization of this new application.”

Ondine’s Photodisinfection System treats Otitis Externa by destroying pathogens and their virulence factors associated with the condition through oxygen-derived, free-radical reactions. Pathogens are rapidly destroyed, thus enabling the affected area to begin healing.

### **About Otitis Externa (Outer Ear Infections)**

Otitis Externa is an inflammation of the outer ear and ear canal often caused by bacteria such as *Pseudomonas aeruginosa* and *Staphylococcus aureus*. Moderate Otitis Externa can result in narrowing of the canal and swelling of soft tissue, while severe Otitis Externa can cause significant obstruction of the ear canal and invasion of soft tissues. The acute form affects four in 1,000 persons annually and the chronic form affects approximately three to five percent of the population. Common treatments include antibiotics, pain killers and steroids. In the United States, approximately 7.5 million prescriptions are written yearly to treat Otitis Externa, costing the healthcare system about US\$310 million.

### **About Ondine Biopharma Corporation**

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on creating and commercializing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is headquartered in Vancouver, British Columbia, Canada, with a research laboratory in Bothell, Washington, USA, and an international office in St. Michael, Barbados. For additional information, please visit the Company’s website at: [www.ondinebiopharma.com](http://www.ondinebiopharma.com).

### **Forward-Looking Statements:**

*Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability*

*to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's filings.*

*The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.*

**FOR FURTHER INFORMATION please contact:**

Carolyn Cross  
President and  
Chief Executive Officer  
Ondine Biopharma Corporation  
(604) 669-0555  
ccross@ondinebiopharma.com

Christina Bessant  
Investor Relations  
The Equicom Group Inc.  
(416) 815-0700 ext. 269  
cbessant@equicomgroup.com

Canaccord Adams Ltd  
Nominated Adviser &  
Broker  
Neil Johnson /  
Ryan Gaffney  
+4420 7050 6500